MX2017005661A - Celulas de mamifero que expresan antigenos de citomegalovirus. - Google Patents

Celulas de mamifero que expresan antigenos de citomegalovirus.

Info

Publication number
MX2017005661A
MX2017005661A MX2017005661A MX2017005661A MX2017005661A MX 2017005661 A MX2017005661 A MX 2017005661A MX 2017005661 A MX2017005661 A MX 2017005661A MX 2017005661 A MX2017005661 A MX 2017005661A MX 2017005661 A MX2017005661 A MX 2017005661A
Authority
MX
Mexico
Prior art keywords
cells expressing
mammalian cells
cytomegalovirus antigens
expressing cytomegalovirus
cmv
Prior art date
Application number
MX2017005661A
Other languages
English (en)
Inventor
Carfi Andrea
Wen Yingxia
Laux Holger
Ciferri Claudio
Hofmann Irmgard
Lilja Anders
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2017005661A publication Critical patent/MX2017005661A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a proteínas de citomegalovirus (CMV) adecuadas para usos en vacunas. En el presente documento se proporcionan células hospederas de mamífero, en particular células CHO, en las que la secuencia o secuencias que codifican las proteínas gH, gL, pUL128, pUL130. pUL131 de CMV (o un fragmento de las mismas que forma complejos) se integran de forma estable en el genoma.
MX2017005661A 2014-10-31 2015-10-29 Celulas de mamifero que expresan antigenos de citomegalovirus. MX2017005661A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14191385.5A EP3015475A1 (en) 2014-10-31 2014-10-31 Mammalian cells expressing cytomegalovirus antigens
PCT/IB2015/058349 WO2016067239A1 (en) 2014-10-31 2015-10-29 Mammalian cells expressing cytomegalovirus antigens

Publications (1)

Publication Number Publication Date
MX2017005661A true MX2017005661A (es) 2017-06-26

Family

ID=51844603

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005661A MX2017005661A (es) 2014-10-31 2015-10-29 Celulas de mamifero que expresan antigenos de citomegalovirus.

Country Status (19)

Country Link
US (1) US10414802B2 (es)
EP (2) EP3015475A1 (es)
JP (1) JP6688297B2 (es)
CN (1) CN107075486B (es)
AR (1) AR102464A1 (es)
BE (3) BE1023364B1 (es)
BR (1) BR112017008827A2 (es)
CA (1) CA2964859C (es)
CY (1) CY1123405T1 (es)
DK (1) DK3212660T3 (es)
ES (1) ES2799735T3 (es)
HR (1) HRP20200932T1 (es)
HU (1) HUE049356T2 (es)
LT (1) LT3212660T (es)
MX (1) MX2017005661A (es)
PL (1) PL3212660T3 (es)
PT (1) PT3212660T (es)
SI (1) SI3212660T1 (es)
WO (1) WO2016067239A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2753138T3 (es) 2012-07-06 2020-04-07 Glaxosmithkline Biologicals Sa Complejos de proteínas de citomegalovirus
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
DK3536776T3 (da) * 2014-04-29 2024-01-15 Novartis Ag Hidtil ukendte vertebratceller og fremgangsmåder til rekombinant ekspression af et polypeptid af interesse
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
WO2018075980A1 (en) 2016-10-21 2018-04-26 Modernatx, Inc. Human cytomegalovirus vaccine
CN107723276B (zh) * 2017-11-02 2021-08-13 上海交通大学 一种稳定高表达目标产物的细胞株的构建方法和试剂盒
SG11202010821TA (en) 2018-05-04 2020-11-27 Spybiotech Ltd Vaccine composition
CA3121915A1 (en) * 2018-12-10 2020-06-18 Km Biologics Co., Ltd. Vaccine for preventing or treating congenital infection with cytomegalovirus
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US20240024455A1 (en) * 2020-12-02 2024-01-25 Seqirus Inc. Multicistronic rna vaccines and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
WO1991006666A1 (en) 1989-11-06 1991-05-16 Cell Genesys, Inc. Production of proteins using homologous recombination
US5589392A (en) 1991-01-14 1996-12-31 Stratagene Nucleic acid construct encoding a nuclear transport peptide operatively linked to an inducible promoter
EP2037959B1 (en) 2006-06-07 2016-01-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
EP4098325A1 (en) * 2010-10-11 2022-12-07 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
ES2753138T3 (es) 2012-07-06 2020-04-07 Glaxosmithkline Biologicals Sa Complejos de proteínas de citomegalovirus
ES2738641T3 (es) 2012-12-18 2020-01-24 Novartis Ag Producción de proteínas terapéuticas en células de mamífero modificadas genéticamente
AU2014369175B2 (en) 2013-12-20 2017-03-02 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
PL3083677T3 (pl) 2013-12-20 2020-03-31 Novartis Ag Nowe komórki eukariotyczne i sposoby rekombinowanej ekspresji produktu będącego przedmiotem zainteresowania
WO2015165480A1 (en) * 2014-04-30 2015-11-05 Institute For Research In Biomedicine Human cytomegalovirus vaccine compositions and method of producing the same
DK3536776T3 (da) 2014-04-29 2024-01-15 Novartis Ag Hidtil ukendte vertebratceller og fremgangsmåder til rekombinant ekspression af et polypeptid af interesse

Also Published As

Publication number Publication date
CA2964859C (en) 2023-04-04
HUE049356T2 (hu) 2020-09-28
PL3212660T3 (pl) 2020-10-05
US20170362278A1 (en) 2017-12-21
BE1023840B1 (fr) 2017-08-10
ES2799735T3 (es) 2020-12-21
BR112017008827A2 (pt) 2018-03-27
BE1023364B1 (fr) 2017-02-20
EP3015475A1 (en) 2016-05-04
CY1123405T1 (el) 2021-12-31
JP6688297B2 (ja) 2020-04-28
SI3212660T1 (sl) 2020-07-31
JP2017534283A (ja) 2017-11-24
LT3212660T (lt) 2020-07-10
WO2016067239A1 (en) 2016-05-06
CN107075486A (zh) 2017-08-18
EP3212660B1 (en) 2020-03-25
DK3212660T3 (da) 2020-06-15
AR102464A1 (es) 2017-03-01
EP3212660A1 (en) 2017-09-06
HRP20200932T1 (hr) 2020-09-18
BE1023840A1 (fr) 2017-08-09
BE1023841B1 (fr) 2017-08-10
PT3212660T (pt) 2020-06-23
US10414802B2 (en) 2019-09-17
CA2964859A1 (en) 2016-05-06
CN107075486B (zh) 2021-06-22
BE1023841A1 (fr) 2017-08-09
BE1023364A1 (fr) 2017-02-20

Similar Documents

Publication Publication Date Title
MX2017005661A (es) Celulas de mamifero que expresan antigenos de citomegalovirus.
MX2023001834A (es) Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
PH12018501280A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
IL251194A0 (en) Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria
MX2018007237A (es) Proteinas de cápside modificadas para un suministro mejorado de vectores de parvovirus.
MX2022009653A (es) Receptores del antigeno quimerico que seleccionan el antigeno para la maduracion de las celulas b.
MY181175A (en) Therapeutic hpv16 vaccines
EA201692025A1 (ru) Доставка белков, осуществляемая на основе бактерий
MX2018002106A (es) Vacunas terapeuticas contra el hpv18.
WO2016046234A3 (en) Recombinant phe-free proteins for use in the treatment of phenylketonuria
WO2014005683A8 (en) Dna vaccine for use in pancreatic cancer patients
MY173638A (en) Parainfluenza virus 5 based vaccines
MX2017008096A (es) Pestivirus.
EP3385286A4 (en) ANTIGEN VACCINE WITH INCREASED IMMUNOGENICITY
EP3151853A4 (en) Novel combinations for antigen based therapy
WO2016116905A9 (en) Cmv antigens and uses thereof
SG10201807572PA (en) Robust antibody purification
GB201017519D0 (en) Vaccines
WO2016077789A8 (en) Neutralizing antibodies to ebola virus glycoprotein and their use
IL265942A (en) A nucleotide sequence expressing an exosome anchor protein for use as a component
MX2016013584A (es) Parvovirus porcino.
MY178774A (en) Uti fusion proteins
EP3226840A4 (en) Antigen delivery system
MX2021009154A (es) Selectividad eficaz de proteinas recombinantes.
MY176630A (en) Oligonucleotide sequence for use in pathway engineering